KALA BIO (NASDAQ:KALA) Issues Quarterly Earnings Results, Beats Expectations By $0.50 EPS

KALA BIO (NASDAQ:KALA) posted its earnings results on Tuesday. The company reported ($1.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.43) by $0.50, Zacks reports.

KALA BIO Trading Down 2.7 %

Shares of KALA traded down $0.19 during trading hours on Thursday, hitting $6.76. 8,705 shares of the stock were exchanged, compared to its average volume of 84,114. The firm has a market capitalization of $31.15 million, a P/E ratio of -0.55 and a beta of -2.13. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.07 and a quick ratio of 3.07. KALA BIO has a fifty-two week low of $4.21 and a fifty-two week high of $10.97. The business has a 50-day moving average of $5.98 and a 200-day moving average of $6.29.

Analyst Upgrades and Downgrades

Separately, Oppenheimer restated an “outperform” rating and issued a $15.00 price objective on shares of KALA BIO in a report on Monday, August 19th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.